Ignite Creation Date:
2025-12-24 @ 5:15 PM
Ignite Modification Date:
2026-01-05 @ 1:45 AM
Study NCT ID:
NCT01884350
Status:
COMPLETED
Last Update Posted:
2019-08-19
First Post:
2013-06-13
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)
Sponsor:
Bristol-Myers Squibb
Organization:
Study Overview
Official Title:
Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)
Status:
COMPLETED
Status Verified Date:
2019-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AEGEAN
Brief Summary:
The study purpose is to assess the impact of an educational program on patient adherence in patients taking Apixaban for SPAF at 24 weeks
Detailed Description:
SPAF=Stroke Prevention in Atrial Fibrillation
ISTH=International Society on Thrombosis and Hemostasis
Primary Purpose: Other: To measure adherence to the study medication using an electronic monitoring device over the first 24 weeks on study medication
ISTH=International Society on Thrombosis and Hemostasis
Primary Purpose: Other: To measure adherence to the study medication using an electronic monitoring device over the first 24 weeks on study medication
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 2013-000055-41 | EUDRACT_NUMBER | None | View |